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Mutations in the progranulin gene (GRN) are an important cause of frontotemporal lobar degeneration (FTLD) with ubiquitin and
TAR DNA-binding protein 43 (TDP43)-positive pathology. The clinical presentation associated with GRN mutations is hetero-
geneous and may include clinical probable Alzheimer’s disease. All GRN mutations identiﬁed thus far cause disease through
a uniform disease mechanism, i.e. the loss of functional GRN or haploinsufﬁciency. To determine if expression of GRN in
plasma could predict GRN mutation status and could be used as a biological marker, we optimized a GRN ELISA and studied
plasma samples of a consecutive clinical FTLD series of 219 patients, 70 control individuals, 72 early-onset probable Alzheimer’s
disease patients and nine symptomatic and 18 asymptomatic relatives of GRN mutation families. All FTLD patients with GRN
loss-of-function mutations showed signiﬁcantly reduced levels of GRN in plasma to about one third of the levels observed
in non-GRN carriers and control individuals (P50.001). No overlap in distributions of GRN levels was observed between the
eight GRN loss-of-function mutation carriers (range: 53–94ng/ml) and 191 non-GRN mutation carriers (range: 115–386ng/ml).
Similar low levels of GRN were identiﬁed in asymptomatic GRN mutation carriers. Importantly, ELISA analyses also identiﬁed
one probable Alzheimer’s disease patient (1.4%) carrying a loss-of-function mutation in GRN. Biochemical analyses further
showed that the GRN ELISA only detects full-length GRN, no intermediate granulin fragments. This study demonstrates
that using a GRN ELISA in plasma, pathogenic GRN mutations can be accurately detected in symptomatic and asymptomatic
carriers. The  75% reduction in full-length GRN, suggests an unbalanced GRN metabolism in loss-of-function mutation carriers
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tool to identify all GRN mutation carriers in early-onset dementia populations and asymptomatic at-risk individuals.
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Introduction
Frontotemporal lobar degeneration (FTLD) is a genetically com-
plex neurodegenerative disorder (Rademakers and Hutton,
2007). It is the second most common form of early-onset demen-
tia after Alzheimer’s disease, accounting for 5–10% of all demen-
tia patients and 10–20% of patients with an onset of dementia
before 65 years (Graff-Radford and Woodruff, 2007). Up to 50%
of patients with FTLD report a family history of dementia, suggest-
ing a strong genetic component to the disease. The clinical
symptoms associated with FTLD are diverse including behaviour
and personality changes, language disorders of expression and
comprehension, cognitive impairment and sometimes motor
neuron disease (McKhann et al., 2001). Three clinical FTLD sub-
types have been deﬁned: behavioural variant frontotemporal
dementia (bvFTD), progressive non-ﬂuent aphasia (PNFA) and
semantic dementia (SD). The most common neuropathology
associated with this type of dementia is FTLD with ubiquitin-
and TAR DNA-binding protein 43 (TDP-43) positive inclusions
(FTLD-U) (Josephs et al., 2004; Lipton et al., 2004; Mackenzie
et al., 2006; Neumann et al., 2006).
In 2006, we identiﬁed loss-of-function mutations in the progra-
nulin gene (GRN) as a major cause of familial FTLD-U, explaining
25% of FTLD-U patients worldwide (Baker et al., 2006; Cruts
et al., 2006; Gass et al., 2006). To date, 63 different pathogenic
GRN loss-of-function mutations have been reported in 169
genealogically unrelated FTLD families (Gijselinck et al., 2008a).
GRN mutations are found scattered over the gene and include
a variety of genetic alterations, such as nonsense and splice-site
mutations as well as small insertions and deletions leading to
a shift in the normal reading frame. Recently, the ﬁrst complete
genomic GRN deletion and a near complete deletion of GRN
exons 1–11 were also reported (Gijselinck et al., 2008b;
Rovelet-Lecrux et al., 2008). Together these studies established
the notion that all GRN mutations share the same pathogenic
mechanism, i.e. the loss of 50% functional GRN, suggesting a
haploinsufﬁciency disease mechanism.
The spectrum of clinical presentations associated with mutations
in GRN is highly heterogeneous (van Swieten and Heutink, 2008).
Behaviour changes are the most common symptoms, although
prominent language impairment is a frequent occurrence during
the course of the disease (Gass et al., 2006; Le Ber et al., 2007;
Rademakers et al., 2007; Beck et al., 2008). Importantly, episodic
memory deﬁcits occur in the initial stage in 10–30% of GRN
mutation carriers, occasionally leading to patients being diagnosed
with Alzheimer’s disease or an amnestic variant of mild cognitive
impairment (Benussi et al., 2008; Brouwers et al., 2007; Josephs
et al., 2007; Kelley et al., 2007; Rademakers et al., 2007).
GRN encodes a secreted precursor protein composed of a signal
peptide sequence and 7.5 tandem repeats of a rare 12 cysteinyl
motif (Bateman and Bennett, 1998). While GRN has growth factor
properties and a weak anti-inﬂammatory effect, it can be proteo-
lytically cleaved by extracellular proteases, such as elastase, to
form a family of peptides, ranging in size from 6 to 25kDa,
called granulins, which are strongly pro-inﬂammatory (Zhu et al.,
2002). Both GRN and the granulins are widely expressed and have
been implicated in a range of biological processes including devel-
opment, wound repair, inﬂammation and tumorigenesis (He and
Bateman, 2003; He et al., 2003). The exact function of GRN in
the brain still remains to be determined; however, a recent in vitro
study suggested that GRN may function as a neurotrophic factor
(Van Damme et al., 2008).
Based on the uniform haploinsufﬁciency disease mechanism
associated with GRN mutations, we hypothesized that the analyses
of GRN levels in plasma using an ELISA could be used to predict
GRN mutation status in patients with FTLD and their asymptomatic
family members. In addition, we sought to test the usefulness of a
GRN ELISA in the identiﬁcation of GRN mutation carriers in patient
populations with other forms of early-onset dementia, such as
probable Alzheimer’s disease (McKhann et al., 1984).
Methods
Participants
Our FTLD study cohort consisted of 219 patients from a consecutive
clinical case series seen at Mayo Jacksonville by the Behavioural
Neurology section. All patients agreed to be in the study and biologi-
cal samples were obtained after informed consent. DNA and plasma
samples were collected and stored using standard procedures. Plasma
was available for 94.5% (207/219) of the patients. Each patient
underwent a full neurological evaluation and all who were testable
had a neuropsychological evaluation. Structural neuroimaging was
performed in all patients, the majority having MRI but a few have
CT. Functional imaging using either single photon emission tomogra-
phy (SPECT) or PET was also performed in most patients. The majority
of patients were followed over time clinically. The diagnoses of the
bvFTD, SD and PNFA were made using the Neary criteria (Neary
et al., 1998). Patients who had Primary Progressive Aphasia and
were ﬂuent (FA) met Mesulam criteria (Mesulam, 2003).
Retrospectively, many but not all of them would meet criteria for
logopenic or mixed aphasia (Gorno-Tempini et al., 2008). Those
with the corticobasal syndrome (CBS) met the criteria outlined by
Boeve (2007). Out of 219 patients with FTLD (50.7% women),
74 patients were diagnosed with bvFTD (including one with
FTD-ALS), 33 with PNFA, 44 with SD, 42 with FA and 26 with
CBS. The mean age at disease onset was 63.9 years (SD 8.3 years,
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family history, deﬁned as having at least one ﬁrst degree relative
with a history of dementia or disease in the FTLD spectrum including
ALS, progressive supranuclear palsy (PSP) and corticobasal degenera-
tion (CBD), was observed. Twenty-one patients underwent autopsy:
16 patients showed pathological diagnoses within the FTLD spectrum,
while ﬁve patients showed Alzheimer’s disease at autopsy.
In addition to the patients included in the consecutive FTLD
series, DNA and plasma samples of eight affected and 18 unaffected
at-risk individuals from three previously published GRN mutation
families ascertained at Mayo Jacksonville and Mayo Rochester were
available (Baker et al., 2006; Gass et al., 2006; Kelley et al., 2007;
Rademakers et al., 2007). DNA and plasma samples of 72 early-onset
probable Alzheimer’s disease patients (mean age at onset SD:
57.9 6.4 years; range: 37–65 years; 61% women) and 70 unrelated
control individuals (mean age SD: 66.3 11.0 years; range: 46–85
years; 50% women) were also ascertained at Mayo Jacksonville.
The clinical diagnoses of Alzheimer’s disease were made using the
NINCDS/ADRDA criteria (McKhann et al., 1984). In collaboration
with Dr Deramecourt we further obtained plasma samples from
the French patient carrying a deletion of GRN exons 1–11 and two
unaffected unrelated control individuals from France (Rovelet-Lecrux
et al., 2008).
Procedures
For sequencing analyses, all 12 coding exons and the non-coding
exon 0 of GRN and exon 1 and exons 9–13 of MAPT were ampliﬁed
by PCR using our previously published primers and protocols (Hutton
et al., 1998; Baker et al., 2006). PCR products were puriﬁed using
AMPure (Agencourt Biosciences, Beverly, MA) then sequenced in
both directions using the Big Dye Terminator v3.1 Cycle Sequencing
kit (Applied Biosystems, Foster City, CA). Sequencing reactions were
puriﬁed using CleanSEQ (Agencourt Biosciences) and analysed on
an ABI3730 Genetic Analyser (Applied Biosystems). GRN sequencing
was previously performed in 64 patients from this cohort as part of
the Mayo Clinic FTLD series, while MAPT sequencing was not pre-
viously performed in this cohort (Gass et al., 2006).
To investigate whether patients who carry the same GRN mutation
are descendants from a common founder, we did a haplotype sharing
study with eight short tandem repeat (STR) markers spanning a region
of 6.9Mb ﬂanking GRN at chromosome 17q21. The STR markers
D17S1299, D17S951, D17S1860, D17S934, D17S950, D17S806,
TAUPROM [an STR marker located in intron 0 of MAPT (Gass
et al., 2006)] and the newly developed GRN_GT15 were PCR ampli-
ﬁed with one ﬂuorescently labeled primer and analysed on an
automated ABI3730 DNA analyser. PCR primers used for GRN_GT15
were F: TCCCATTTCTCCCTTCTAGTTG and R: AAGTTGAGGCTG
CAGGGTG. Alleles were scored using the GENOTYPER software
(Applied Biosystems).
Genotyping of control individuals for GRN variant c.415T4C
(p.C139R) was performed with a TaqMan chemistry-based allelic dis-
crimination assay, with Assay by Design probes (Applied Biosystems)
and an Applied Biosystems 7900 PCR system, followed by analysis
with Sequence Detection System 2.2.1 software (Applied Biosystems).
To determine GRN expression levels in human plasma samples,
we used the human Progranulin ELISA kit (Adipogen Inc., Seoul,
Korea) using a 1:100 dilution of the plasma samples in 1  diluent
following manufacturer’s instructions. The wash solution was
aspirated after each third wash to ensure that all residual wash solu-
tion was removed. To increase accuracy all samples were analysed
twice in two independent experiments using six interplate control
samples for normalization. Based on our FTLD population (n=207),
the median coefﬁcient of variation (CV) was 3.2%. Recombinant
human GRN provided with the ELISA kit was used as a standard.
For Western blot analyses, albumin depleted plasma samples
(SwellGel Blue Albumin Removal Kit, Pierce, Rockford, IL) and protein
samples extracted from cerebellar brain homogenates of FTLD
patients with and without GRN mutations, were separated by SDS–
PAGE using pre-cast 4–20% Tris–Glycine gels (Invitrogen, Carlsbad,
CA) and transferred to nitrocellulose membranes. GRN levels were
assessed using the GRN capture antibody and the GRN detection
antibody used in the ELISA (Adipogen Inc.). GRN cleavage products
were obtained by elastase treatment of recombinant GRN for 30min
at 25 C (Athens Research & Technology, Athens, GA).
Statistical analyses
GRN expression levels were compared between two groups using
Mann–Whitney tests. The Kruskal–Wallis test was used to compare
GRN expression across clinical FTLD subtypes. Results were considered
statistically signiﬁcant for P40.05; no adjustments were made for
multiple testing; however, results were interpreted cautiously in the
light of the number of tests conducted in these exploratory analyses.
Since there was no overlap in distributions of GRN expression levels in
the GRN loss-of-function mutation carriers compared to the non-GRN
carriers, we explored sensitivity and speciﬁcity for various cut-off
points on a continuous scale by ﬁtting normal distributions to the
square root of the GRN levels. Ten thousand bootstrap samples
were then obtained to construct 95% conﬁdence intervals for sensi-
tivity and speciﬁcity at a range of potential cut-off values.
Results
We performed systematic mutation analyses of GRN and MAPT
through direct sequencing in all 219 patients diagnosed with FTLD
from a consecutive clinical case series ascertained at Mayo
Jacksonville. In MAPT, we identiﬁed the known pathogenic muta-
tion, IVS10+16C4T, in intron 10 in a single patient (NGR180),
who presented with personality changes at the age of 55 and was
diagnosed with bvFTD. His father, paternal uncle and aunt also
had early-onset dementia. Imaging analyses in this patient showed
bilateral temporal atrophy on MRI as well as bilateral temporal
hypometabolism on PET.
In GRN, we identiﬁed ﬁve different pathogenic loss-of-function
mutations in a total of eight patients with FTLD and a previously
published partial deletion of exon 11, IVS10-15_Ex11+178del, in
a single patient with FTLD (Table 1). We further identiﬁed four
missense mutations, two silent mutations and one regulatory
variant, 50UTR-22C4T, in eight patients with FTLD (Table 1).
With the exception of the silent mutation, p.P578, these GRN
variants were previously published, however, their pathogenic
nature largely remains unknown. Samples were not available
from other family members to test for segregation of these GRN
variants. The presence of missense mutation p.C139R (c.415C4T),
which had not been identiﬁed in control individuals in previous
studies, was further excluded in 248 control individuals ascer-
tained at Mayo Jacksonville. A summary of the clinical and
pathological characteristics of the GRN mutation carriers is
provided in Table 1.
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Patient
(alias)
Predicted cDNA mutation
Predicted protein mutation
Sex Age at
onset
Family
history
Clinical
Dx
Initial
clinical
Structural
neuroimaging
Functional
neuroimaging
Pathology Reference to
patient
(death) symptom
GRN loss-of-function mutations
NGR019 c.26C4A F 56 Y PNFA Aphasia MRI: perisylvian Not done (Gass et al., 2006;
(11696) p.A9D (L4R) atrophy Kelley et al., 2007)
NGR001 c.388_391delCAGT M 65 (75) N PNFA Aphasia MRI: temporal and Not done FTLD-U (NII)+ This study
p.Q130SfsX125 perisylvian (L) atrophy HpScl
NGR077 c.388_391delCAGT M 50 Y bvFTD Personality MRI: generalized FDG-PET: frontal This study
p.Q130SfsX125 atrophy (L4R) hypometabolism
NGR228 c.911_912insTG M 63 N bvFTD Aphasia/ MRI: frontal (L4R) FDG-PET: frontal This study
p.W304LfsX58 Personality atrophy (L4R) hypometabolism
NGR192 c.911_912insTG F 49 Y FA Aphasia MRI: parietal, FDG-PET: parietal and This study
p.W304LfsX58 perisylvian and
temporal (L) atrophy
temporal (L) hypometabolism
NGR003 c.998delG M 65 (73) Y PNFA Aphasia MRI: perisylvian Not done FTLD-U (NII) (Gass et al., 2006;
(PPA-1D) p.G333VfsX28 (L) atrophy +HpScl Mesulam et al., 2007)
NGR043 c.1477C4T F 64 (69) Y bvFTD Personality MRI: moderate Not done (Rademakers et al., 2007)
(2619) p.R493X frontal and temporal
(L+R) atrophy
NGR068 c.1477C4T M 48 (50) N FA Aphasia MRI: mild FDG-PET: temporal (Rademakers et al., 2007)
(7756) p.R493X ventricular enlargement
in frontal horn
(L+R), frontal and parietal (L)
hypometabolism
NGR247 c.1414-15_1590del
p.A472_Q548del
F 79 (86) N SD Anomia CT: temporal atrophy (L) Not done This study
GRN mutations with unknown pathogenic nature
NGR022 c.55C4T F 61 N bvFTD Personality MRI: frontal and Not done (Gass et al., 2006)
p.R19W temporal (L+R) atrophy
NGR139
a c.415T4C M 76 Y FA Aphasia MRI: mild FDG-PET: parietal and This study
p.C139R generalized atrophy temporal (L) hypometabolism
NGR221 c.970G4A M 64 (70) N PNFA Apraxia of MRI: temporal and Not done CBD This study
p.A324T speech parietal (L4R) atrophy
NGR039 c.1297C4T M 66 N PNFA Aphasia MR: sylvian and Not done (Gass et al., 2006)
p.R433W temporal (L) atrophy
NGR105 c.1297C4T F 61 Y SD Anomia MRI: temporal FDG-PET: left This study
p.R433W (L4R) atrophy hemisphere hypometabolism
NGR167 c.1297C4T M 68 Y FA Aphasia MRI: slight FDG-PET: temporal This study
p.R433W enlargement of the
sylvian ﬁssure (L)
and perisylvian (L)
hypometabolism
NGR084 c.1341C4T F 64 Y bvFTD Personality MRI: frontal (R4L) FDG-PET: frontal This study
p.H447 atrophy (R4L) hypometabolism
NGR225 c.1734G4A F 55 N PNFA Aphasia MRI: temporal Not done This study
p.P578 (L4R) atrophy
a Patient NGR139 also carries the rare 50UTR-22C4T promoter variant. PNFA=Progressive non-ﬂuent aphasia. bvFTD=behavioural variant frontotemporal dementia. FA=Fluent aphasia. SD=Semantic dementia.
CBD=Corticobasal degeneration. R=right. L=Left. MRI=Magnetic resonance imaging. CT=computerized tomography. FDG-PET=18F-ﬂuorodeoxyglucose positron emission tomography. FTLD-U=frontotemporal lobar
degeneration with ubiquitin inclusions. NII=intranuclear inclusions. HpScl=Hippocampal sclerosis.
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genomic region ﬂanking GRN showed shared alleles for seven
consecutive markers for patients NGR001 and NGR077
carrying p.Q130SfsX125 and shared alleles for all eight con-
secutive markers for patients NGR192 and NGR228 carrying
p.W304LfsX58, suggesting a common genetic origin for each
of these GRN mutations. A common founder for patients
NGR043 and NGR068 carrying p.R493X had previously been
reported (Gass et al., 2006).
We then determined whether the levels of GRN in plasma
could be used to distinguish GRN loss-of-function mutation
carriers from non-GRN carriers in our FTLD series. Using a GRN
ELISA we analysed a subset of 207 patients with FTLD from our
consecutive cohort with plasma availability, including seven loss-
of-function GRN mutation carriers and patient NGR247 carrying
the partial GRN deletion, p.A472_Q548del. A signiﬁcant reduction
in GRN levels was observed in all patients carrying GRN loss-of-
function mutations to about one third of the level observed
in non-GRN carriers (Fig. 1; Table 2). GRN levels ranged from
53 to 94ng/ml (mean value SD: 68 16ng/ml) in mutation
carriers, while non-GRN carriers showed levels from 115 to
386ng/ml (mean value SD: 220 47ng/ml). Interestingly,
GRN levels were variable among GRN mutation carriers with
slightly higher expression in NGR019 (88ng/ml) carrying the
p.A9D mutation in the signal peptide sequence and NGR247
(94ng/ml) carrying p.A472_Q548del, compared to the typical
frameshift and nonsense mutation carriers (Fig. 2). Based on our
data alone, any cut-off value between 94 and 115ng/ml is asso-
ciated with crude estimates of both sensitivity and speciﬁcity of
100%. By assuming normality of GRN levels after a square root
transformation, we were able to explore continuous estimates of
sensitivity and speciﬁcity with different cut-off values (Table 3).
A cut-off value of 112ng/ml maximized the average of the esti-
mates of sensitivity and speciﬁcity. GRN levels in 70 control
individuals ranged from 138 to 376ng/ml (mean value SD:
228 50ng/ml) comparable to patients with FTLD without
GRN mutations (Fig. 1). As expected, normal GRN expression
(259ng/ml) was observed in our MAPT mutation carrier.
Within the group of patients carrying GRN mutations with
unknown pathogenic nature, NGR139 (p.C139R) and NGR022
(p.R19W) showed relatively low expression of GRN, in the
range of the lowest 3% of patients without GRN mutations
(p.C139R: 124.2ng/ml; p.R19W: 135.9ng/ml) and below the
GRN levels observed in control individuals. Although these
GRN levels fall outside the range of the typical loss-of-function
mutations, these mutations may induce a partial loss-of-function.
In contrast, the GRN levels in the other missense mutation carriers
and silent mutation carriers were well within the normal range
(Fig. 2).
In the group of non-GRN mutation carriers, a signiﬁcant gen-
der difference in plasma GRN expression levels was observed
with higher levels in females (mean value SD: 230 48ng/ml)
compared to males (mean value SD: 210 44ng/ml) (P50.001;
Table 2). In exploratory analysis of subgroups by age and gender,
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Figure 1 Plasma GRN levels in FTLD patients and control
individuals. Plasma GRN protein levels (ng/ml) in patients with
FTLD carrying loss-of-function GRN mutations (n=8), FTLD
patients without GRN mutations (n=191) and healthy control
individuals (n=70). Each data point represents an individual.
Plasma levels are signiﬁcantly decreased in loss-of-function
GRN mutation carriers compared to non-GRN mutation carriers
(P50.001; Mann–Whitney test). For each group the median
plasma level is indicated with a wide horizontal line. For larger
groups (FTLD patients without GRN mutation carriers and
healthy control individuals) 25% and 75% quantiles are shown
with short horizontal lines.
Table 2 Summary of plasma GRN expression levels in
patients with FTLD
Plasma GRN levels (ng/ml)
Variable N Median IQR Range P-value
Loss-of-function GRN mutation
a
Yes 8 59 57–81 53–94 50.001
No 191 213 186–249 115–386
Gender
b
Male 95 203 183–233 130–370 0.0011
Female 96 233 196–258 115–386
Family history
b
Yes 74 219 185–249 115–386 0.80
No 117 211 186–250 130–307
Clinical FTLD subtypes
b
bvFTD 62 218 189–258 143–370 0.61
PNFA 27 216 187–260 115–386
SD 40 212 187–235 137–278
FA 37 205 180–248 127–310
CBS 25 230 188–249 130–360
a Patients carrying GRN mutations with unknown pathogenic nature were
excluded.
b Patients carrying GRN mutations were excluded.
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while remaining constant in females, however these ﬁndings
did not reach signiﬁcance (data not shown). Also, the gender
difference was not conﬁrmed in our control cohort. No signiﬁ-
cant differences in GRN plasma levels were observed between
patients with a positive and negative family history of dementia
or between patients with each of the ﬁve clinical subtypes of
FTLD (Table 2). Also, no correlation between GRN expression
levels and the age of disease onset in GRN mutation carriers or
non-GRN mutation carriers was observed.
To further characterize the effect of GRN mutations on the
levels of GRN in plasma, we performed a GRN ELISA on nine
affected (one proband included in the consecutive FTLD series
and eight additional patients) and 18 unaffected at-risk individ-
uals from three previously published GRN mutation families with
typical loss-of-function mutations (p.T52HfsX2, p.T382SfsX30
and p.R493X) ascertained at Mayo Jacksonville and Mayo
Rochester. Six of the 18 asymptomatic at-risk individuals were
identiﬁed as GRN mutation carriers using DNA sequencing ana-
lyses. We observed signiﬁcantly lower GRN levels in both symp-
tomatic and asymptomatic GRN mutation carriers, than non-GRN
mutation carriers (P50.001; Fig. 3).
Table 3 Estimated sensitivity and speciﬁcity of the GRN
ELISA assay using different cut-off values
Plasma GRN level
cut-point (ng/ml)
Sensitivity (95% CI)
a Speciﬁcity (95% CI)
a
100 97.42 (86.90–100) 99.88 (99.66–99.97)
105 98.64 (90.67–100) 99.80 (99.48–99.94)
110 99.32 (93.37–100) 99.67 (99.23–99.89)
112 99.49 (94.62–100) 99.61 (99.87–99.10)
115 99.67 (95.35–100) 99.49 (98.89–99.81)
120 99.85 (96.75–100) 99.23 (98.42–99.70)
125 99.93 (97.79–100) 98.86 (97.81–99.53)
130 99.97 (98.56–100) 98.36 (97.04–99.26)
135 99.99 (99.11–100) 97.71 (96.06–98.89)
a Estimate based on assumption of normally distributed GRN levels after square
root transformation. Conﬁdence intervals constructed by parametric bootstrap
method.
0
25
50
75
100
125
150
175
200
225
250
275
300
325
P
l
a
s
m
a
 
G
R
N
 
l
e
v
e
l
s
 
(
n
g
/
m
l
)
Symptomatic
GRN +
Asymptomatic
GRN +
Relatives
GRN −
Figure 3 Plasma GRN levels in symptomatic and
asymptomatic GRN mutation carriers in three GRN mutation
families. Plasma GRN protein levels (ng/ml) in patients and
relatives of three GRN mutation families ascertained in Mayo
Jacksonville and Rochester: Symptomatic GRN mutation
carriers (n=9), asymptomatic GRN mutation carriers (n=6)
and relatives without GRN mutations (n=12). Plasma levels are
signiﬁcantly decreased in symptomatic and asymptomatic GRN
mutation carriers compared to relatives without GRN mutations
(P50.001; Mann–Whitney test). Each data point represents
an individual. For each group, the median plasma level is
indicated with a wide horizontal line.
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Figure 2 Speciﬁc plasma GRN levels in all types of GRN
mutations. GRN expression is plotted for each patient with
FTLD from our cohort carrying a GRN mutation. Black bars
represent patients with FTLD carrying pathogenic GRN loss-of-
function mutations; grey bars represent patients with FTLD
carrying GRN mutations with unknown signiﬁcance. The
dashed line is the cut-off value for pathogenic GRN loss-of-
function mutations based on the complete FTLD series and the
black line indicates the minimum GRN expression identiﬁed in
our control cohort (Fig. 1). Missense mutations p.R19W and
p.C139R show GRN levels below the range detected in control
individuals and may induce a partial loss of GRN function.
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(n=8), were explained by pathogenic loss-of-function mutations
identiﬁed by direct sequencing. Since the presence of a partial
or complete GRN gene deletion/duplication is expected to have
a similar effect on GRN expression, e.g. the loss of 50% of GRN,
these data suggest the absence of GRN copy-number mutations
in our series. To further conﬁrm this ﬁnding, we performed a GRN
ELISA on plasma obtained from the previously published French
patient carrying a near complete deletion of GRN including exons
1–11 [patient II.4 from original publication (Rovelet-Lecrux et al.,
2008)] and two unrelated French control individuals. These anal-
yses showed a strongly reduced expression of GRN (86.2ng/ml)
in the GRN deletion carrier, compared to control individuals
(196.6 and 263.2ng/ml).
Next, we performed a GRN ELISA in a population of 72 patients
with a clinical diagnosis of early-onset Alzheimer’s disease. In one
patient, strongly reduced GRN expression levels (74ng/ml)
were observed and sequencing analyses showed a novel loss-
of-function mutation c.592_593delAG in GRN exon 5, which is
expected to result in a shift of the normal reading frame and
a premature termination codon (p.R198GfsX19). This patient
presented at the age of 63 years with an amnestic syndrome
which was conﬁrmed on neuropsychology. MRI showed mild
atrophy including frontal atrophy. No family history of dementia
was reported. He met NINCDS/ADRDA criteria for probable
Alzheimer’s disease (McKhann et al., 1984). GRN levels in
the other 71 patients with Alzheimer’s disease without GRN
mutations ranged from 143 to 368ng/ml (mean value   SD:
238 53ng/ml), comparable to GRN levels in control individuals.
Finally, to gain more insight into the processing of GRN and
to determine which GRN species are detected by the ELISA,
we performed GRN Western blot analyses on plasma samples
and brain homogenates of FTLD patients with and without GRN
mutations. These studies indicated that the antibodies used in
the ELISA could only detect full-length GRN, no intermediate
GRN fragments or recombinant GRN cleavage products.
Discussion
The range of mutations identiﬁed in GRN over the past 2 years
established GRN haploinsufﬁency as the uniform disease mecha-
nism underlying FTLD in GRN mutation carriers (Gijselinck et al.,
2008a). Microarray data further showed signiﬁcantly reduced
GRN mRNA expression in peripheral blood in GRN loss-of-
function mutation carriers compared to non-mutation carriers
(Coppola et al., 2008). These ﬁndings raised the important
question as to whether expression of GRN in plasma could
predict GRN mutation status and could be used as a biological
marker to identify GRN mutation carriers.
To answer this question, we ﬁrst studied a large consecutive
series of clinical FTLD patients ascertained at Mayo Jacksonville,
for which DNA and plasma samples were available. Direct sequen-
cing analyses of GRN identiﬁed six different GRN loss-of-function
mutations in nine FTLD patients explaining the disease in 4.1%
(9/219) of the population and 5.7% (5/87) of FTLD patients
with a positive family history. This GRN mutation frequency
is very similar to our previously reported mutation frequency of
4.8% in an unbiased subpopulation of US FTLD patients (Gass
et al., 2006). GRN mutations included typical nonsense and
frameshift mutations as well as the previously reported p.A9D
mutation in the signal peptide sequence of GRN, and a partial
deletion of GRN exon 11, which extends from 15-bp upstream
of exon 11 to 177-bp in exon 11 and is predicted to result in an
in-frame deletion of exon 11 (p.A472_Q548del) (Gass et al.,
2006; Mukherjee et al., 2006, 2008; Pickering-Brown et al.,
2006; Kelley et al., 2007; Spina et al., 2007). GRN expression
studies in the complete FTLD cohort using a GRN ELISA demon-
strated that plasma GRN levels were strongly reduced in all
loss-of-function GRN mutation carriers compared to non-GRN
mutation carriers (P50.001). Even though we observed a wide
range in GRN expression in FTLD patients and control individuals,
all mutation carriers showed signiﬁcantly reduced GRN levels to
about one third of the levels observed in non-GRN carriers and
control individuals. In our series, a plasma GRN cut-off value of
112ng/ml distinguished all GRN mutation carriers from non-GRN
carriers and we therefore expect it to have close to 100% sensi-
tivity and speciﬁcity in future samples. These results are in line
with a recently published study by Ghidoni et al. (2008) who
established that in an Italian FTLD population a GRN cut-off
level of 110.9ng/ml was 92.8% speciﬁc and 100% sensitive to
identify GRN mutations. However, since there were only eight
GRN mutation carriers in our FTLD population, further carriers
will need to be assessed to more deﬁnitively decide on the opti-
mal cut-off; in the meantime it may be prudent to use a higher
threshold than 112ng/ml to be more certain of a high sensitivity,
without materially lowering speciﬁcity. For example, examining
Table 3 we see that a cut-off value of 135ng/ml has a lower
conﬁdence limit for sensitivity of 499%, and this is achieved
with an estimated speciﬁcity of 97.7%.
Interestingly, we showed strongly reduced GRN expression in
patients carrying all types of loss-of-function GRN mutations,
including patient NGR019 carrying the p.A9D signal peptide muta-
tion and patient NGR247 carrying the partial GRN deletion,
p.A472_Q548del. We also conﬁrmed similar low levels of GRN
in a French patient with clinical Parkinson’s disease carrying a
near complete deletion in GRN.
Next, by analysing unaffected relatives carrying GRN mutations,
we showed that the GRN reduction is independent of the disease
status, suggesting that the GRN ELISA could also function as
a diagnostic tool to identify asymptomatic GRN mutation carriers.
GRN sequencing analyses in our cohort of FTLD patients also
identiﬁed four different GRN missense mutations with unknown
pathogenic nature in six FTLD patients. The plasma GRN levels
in these missense mutation carriers generally supported the
previously predicted effect on GRN function based on in silico
structural protein modeling analyses (Brouwers et al., 2008;
Gijselinck et al., 2008a). Mutation p.C139R was predicted to be
likely pathogenic because of a destabilizing effect on the granulin-
fold by disrupting one of the cysteine disulﬁde bridges. This muta-
tion had been previously reported in an Italian early-onset familial
FTD patient and a Belgian late-onset Alzheimer’s disease patient,
while absent in 4900 control individuals that were analysed by
us and others (Bernardi et al., 2008; Brouwers et al., 2008).
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with FA at the age of 76 years. His problem began with language
difﬁculty including expression and comprehension. Sentence repe-
tition was preserved. Picture description was normal except for
some mild anomia. MRI showed mild non-asymmetrical atrophy.
PET analyses showed hypometabolism in the left parietotemporal
area and neuropsychometric testing indicated deﬁcits in language,
frontal function and preserved memory. In line with the predic-
tions, low amounts of GRN were measured in the plasma sample
of this patient (124ng/ml), supporting the pathogenic potential
of this mutation through a partial loss of GRN function. In con-
trast, all four patients carrying missense mutations p.A324T and
p.R433W, which were predicted by in silico analyses to be toler-
ated, and both carriers of the silent GRN mutations (p.H447 and
p.P578) showed GRN plasma levels within the normal range.
Although we cannot exclude the possibility that these mutations
abolish GRN function without reducing the overall expression of
GRN, these ﬁndings suggested that plasma GRN levels may be
a valuable tool in predicting the pathogenic potential of GRN
mutations. We propose that individuals carrying intermediate
levels of GRN ( 110–140ng/ml) undergo additional genetic test-
ing to determine the presence of potential pathogenic GRN mis-
sense mutations.
Previous studies have reported clinical Alzheimer’s disease diag-
noses in patients carrying loss-of-function mutations in GRN
(Boeve, 2007; Kelley et al., 2007). In a clinicopathological
study, we performed on the most common GRN mutation world-
wide, p.R493X, 10% of the mutation carriers received a primary
clinical diagnosis of Alzheimer’s disease and memory impairment
was the second most common initial clinical symptom, affecting
30% of the mutation carriers (Rademakers et al., 2007). In
this study, using our GRN ELISA as a screening tool, we analysed
72 patients with clinically diagnosed early-onset probable
Alzheimer’s disease for mutations in GRN and identiﬁed one
patient (1.4% of the population) carrying a loss-of-function muta-
tion. If a disease modifying treatment for either Alzheimer’s
disease or FTLD becomes available in the future, then, based on
the ﬁnding above and knowing that that FTLD usually starts
early, one could make the case that it would be reasonable to
screen early-onset probable Alzheimer’s disease cases with a
plasma measure for GRN.
In our study, plasma GRN levels were  75% reduced in muta-
tion carriers with respect to non-GRN patients and controls,
which is signiﬁcantly more than expected based on the haploin-
sufﬁciency disease mechanism. A similar reduction in GRN expres-
sion was recently reported in an Italian series of GRN mutation
carriers (Ghidoni et al., 2008). In contrast, only 35–50% reduc-
tions in GRN mRNA levels have been reported in GRN mutation
carriers (Baker et al., 2006). These ﬁndings, together with the fact
that we established that only full-length GRN and no granulins
or intermediate GRN fragments can be detected by our ELISA,
predict an unbalanced GRN metabolism in GRN mutation carriers,
whereby the processing of GRN into granulins is increased. This
would suggest that patients with GRN mutations may speciﬁcally
lack full-length GRN, while maintaining normal levels of granulins.
This is an interesting ﬁnding which may have implications for
future therapeutic strategies, especially since GRN and the
proteolytically derived granulin fragments each have distinct bio-
logical properties, e.g. GRN functions as a growth factor or anti-
inﬂammatory agent, while granulin peptides boost inﬂammation
(Zhu et al., 2002; He and Bateman, 2003; Ahmed et al., 2007).
In future experiments, detailed biochemical analysis of the secre-
tion and proteolytic processing of GRN in mutation carriers and
control individuals will be essential.
In conclusion, this large study of GRN expression in patients
with FTLD, Alzheimer’s disease and control individuals provides
strong support for the use of a GRN ELISA as a reliable and
inexpensive tool to identify GRN mutation patients and carriers.
Moreover, compared to classical mutation screening of GRN by
sequencing analyses, a GRN ELISA has the important advantage
of identifying individuals carrying all types of mutations including
GRN deletions.
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